<DOC>
	<DOCNO>NCT01802502</DOCNO>
	<brief_summary>Tuberculous ( TB ) meningitis severe manifestation TB infection , leave 50 % patient dead neurologically disable . Current treatment similar treatment lung TB , although penetration antibiotic brain poor immune-pathology TB meningitis different pulmonary TB . In recent phase II clinical trial investigator group , first kind globally , intensified antibiotic treatment , moxifloxacin high dose rifampicin , strongly reduce mortality TB meningitis . The investigator aim examine effect intensify antibiotic treatment mortality morbidity TB meningitis phase 3 clinical trial , precede explorative pharmacokinetic ( PK ) study examine high oral dos rifampicin result exposure similar i.v . dose used phase 2 trial , since oral rifampicin could implement much easy low-resource setting .</brief_summary>
	<brief_title>Rifampicin Explorative PK Study Tuberculous Meningitis Comparing Oral Intravenous Preparation</brief_title>
	<detailed_description>Introduction : In recent clinical trial investigator show high dose rifampicin administer intravenously ( 600 mg iv ) first 2 week treatment safe associate survival benefit adult TB meningitis . An oral ( rather iv ) dose would help implementation intensified treatment TB meningitis . However , hard predict oral dose rifampicin result rifampicin exposure similar 600 mg iv , due difference bio-availability ( oral vs. iv ) unpredictable dose-concentration relationship ( nonlinear pharmacokinetics rifampicin ) . Therefore investigator aim examine pharmacokinetic 2 high dos rifampicin ( 750 mg 900 mg ) give orally , compare pharmacokinetic profile result previous study use 600 mg rifampicin iv . General Objective : To help establish optimize treatment regimen TB meningitis Specific Objectives : 1 . To explore whether exposure result oral rifampicin 750 mg 900 mg similar exposure intravenous rifampicin 600 mg first two day treatment 2 . To explore whether exposure result oral rifampicin 750 mg 900 mg similar exposure 14 day treatment ( stabilize rifampicin concentration , i..e steady-state ) 3 . To evaluate safety tolerability high dose oral rifampicin 4 . To evaluate neurological response mortality 2 week treatment high dose rifampicin Study Design : Explorative pharmacokinetic study ; randomize , three-arm , two-period evaluation . Study procedure : After diagnosis TB meningitis , eligible patient randomize get either oral 750 mg , oral 900 mg , iv 600 mg rifampicin 14 day combination standard oral TB drug ( isoniazid 300 mg/day , ethambutol 750 mg/day , pyrazinamide 1500mg/day ) adjuvant dexamethasone i.v . pyridoxine . Serial blood sample take 6 time 0 , 1 , 2 , 4 , 8 , 12 hour drug administration first second day treatment day 14 ( steady-state ) . Single cerebrospinal fluid ( CSF ) sample take 3-6 hour administration day blood sampling day .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Meningeal</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Age 18 year older Probable/possible tuberculosis meningitis use uniform case definition Agree participate study Patient antituberculosis treatment within last 2 week . Increase liver function &gt; 5x upper limit normal Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>tuberculous meningitis</keyword>
	<keyword>rifampicin</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>oral administration</keyword>
	<keyword>intravenous administration</keyword>
</DOC>